World · India Bureau
US regulators add vision loss warning to popular weight loss drugs
The US Food and Drug Administration has mandated new labeling warnings for a class of blockbuster weight loss medications following reports of a rare eye condition that can cause permanent vision loss. The warning will apply to all GLP-1 drugs, including widely-used brands Ozempic, Wegovy, Zepbound and Mounjaro.
LSN India ·
The FDA announced Monday that manufacturers of GLP-1 receptor agonist drugs must add warnings about non-arteritic anterior ischemic optic neuropathy (NAION) to their product labeling. The eye condition, which involves decreased blood flow to the optic nerve, can result in significant and sometimes irreversible vision loss.
The class of medications affected comprises approximately a dozen injectable and oral drugs used to treat obesity, type 2 diabetes and other conditions. While the exact mechanism causing NAION remains unclear, the FDA said the condition has been reported across all GLP-1 drugs currently on the market.
The regulatory action follows a 2024 medical publication linking the eye condition to patients taking semaglutide, the active ingredient in Ozempic and Wegovy. This prompted FDA scientists to conduct a comprehensive review of adverse event reports across the entire GLP-1 drug class.
The warning addition reflects ongoing efforts by health regulators to ensure patients and healthcare providers have complete information about potential risks associated with these increasingly popular medications. Patients currently taking GLP-1 drugs should consult their physicians regarding any vision changes or concerns.